aln-agt01
Nucleic acidexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2019 (NCT03934307)
Timeline
Indications
Mechanism of action
- AngiotensinogenINHIBITOR
AGT inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095298 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07181109 | Phase 3 | Sep 22, 2025 | Alnylam Pharmaceuticals, Roche |
| NCT06675565 | Phase 1 | Nov 5, 2024 | Alnylam Pharmaceuticals |
| NCT06423352 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2024 | Alnylam Pharmaceuticals |
| NCT06272487 | Phase 2 | Feb 29, 2024 | Alnylam Pharmaceuticals |
| NCT05103332 | Phase 2 | Oct 26, 2021 | Alnylam Pharmaceuticals |
| NCT04936035 | Phase 2 | Jul 7, 2021 | Alnylam Pharmaceuticals |
| NCT03934307 | Phase 1 | May 1, 2019 | Alnylam Pharmaceuticals |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 7 | 7 | 3 | 2019 |
| Roche | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1